Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2011, Article ID 194296, 3 pages
http://dx.doi.org/10.1155/2011/194296
Case Report

Malignant Hyperthermia and Idiopathic HyperCKemia

International Scholars Program, Department of Internal Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15213, USA

Received 19 September 2011; Accepted 12 October 2011

Academic Editor: Piotr K. Janicki

Copyright © 2011 Pashtoon Murtaza Kasi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Figarella-Branger, G. Kozak-Ribbens, L. Rodet et al., “Pathological findings in 165 patients explored for malignant hyperthermia susceptibility,” Neuromuscular Disorders, vol. 3, no. 5-6, pp. 553–556, 1993. View at Google Scholar · View at Scopus
  2. M. R. Weglinski, D. J. Wedel, and A. G. Engel, “Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels,” Anesthesia and Analgesia, vol. 84, no. 5, pp. 1038–1041, 1997. View at Google Scholar
  3. A. Malandrini, A. Orrico, C. Gaudiano et al., “Muscle biopsy and in vitro contracture test in subjects with idiopathic HyperCKemia,” Anesthesiology, vol. 109, no. 4, pp. 625–628, 2008. View at Publisher · View at Google Scholar · View at PubMed
  4. Y. S. Lee, W. Y. Kim, S. H. Lee et al., “A case of malignant hyperthermia during anesthesia induction with sevoflurane,” Korean Journal of Anesthesiology, vol. 59, pp. S6–S8, 2010. View at Publisher · View at Google Scholar · View at PubMed
  5. S.-C. Hsu, W.-T. Huang, H.-M. Yeh, and A. Y.-J. Hsieh, “Suspected malignant hyperthermia during sevoflurane anesthesia,” Journal of the Chinese Medical Association, vol. 70, no. 11, pp. 507–510, 2007. View at Publisher · View at Google Scholar
  6. H. Rosenberg, M. Davis, D. James, N. Pollock, and K. Stowell, “Malignant hyperthermia,” Orphanet Journal of Rare Diseases, vol. 2, article 21, 2007. View at Publisher · View at Google Scholar · View at PubMed
  7. M. Capasso, M. V. De Angelis, A. Di Muzio et al., “Familial idiopathic hyper-CK-emia: an underrecognized condition,” Muscle and Nerve, vol. 33, no. 6, pp. 760–765, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. N. Monnier, G. Kozak-Ribbens, R. Krivosic-Horber et al., “Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility,” Human Mutation, vol. 26, no. 5, pp. 413–425, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. B. A. Britt, L. Endrenyi, and P. L. Peters, “Screening of malignant hyperthermia susceptible families by creatine phosphokinase measurement and other clinical investigations,” Canadian Anaesthetists Society Journal, vol. 23, no. 3, pp. 263–284, 1976. View at Google Scholar
  10. The North American MH Registry of Malignant Hyperthermia Association of United States (MHAUS), http://www.mhaus.org/.
  11. “List of anesthesia agents that can cause MH,” September 2011, http://medical.mhaus.org/index.cfm/fuseaction/Content.Display/PagePK/AnestheticList.cfm.
  12. P. M. Hopkins, “Malignant hyperthermia: pharmacology of triggering,” British Journal of Anaesthesia, vol. 107, no. 1, pp. 48–56, 2011. View at Publisher · View at Google Scholar · View at PubMed